MedTrace Logo

A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults

NCT02994381 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-01-27

No results posted yet for this study

Summary

This will be an open-label, non-randomized, single oral dose study in healthy male subjects.

All subjects will receive a single oral dose of 10 mL of \[14C\]-RPC1063 Solution (0.1 mg/mL), containing NMT 1.3 MBq (37 μCi) 14C.

Conditions

  • Healthy Volunteers

Interventions

DRUG

RPC1063

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Jonathan Tran, Pharm.D · Celgene Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02994381 on ClinicalTrials.gov